REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
13.16
+0.18 (1.39%)
At close: Dec 5, 2025, 4:00 PM EST
13.16
0.00 (0.00%)
After-hours: Dec 5, 2025, 5:01 PM EST
REGENXBIO Market Cap
REGENXBIO has a market cap or net worth of $666.20 million as of December 5, 2025. Its market cap has increased by 40.64% in one year.
Market Cap
666.20M
Enterprise Value
632.30M
1-Year Change
40.64%
Ranking
Category
Stock Price
$13.16
Market Cap Chart
Since September 17, 2015, REGENXBIO's market cap has decreased from $749.30M to $666.20M, a decrease of -11.09%. That is a compound annual growth rate of -1.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 5, 2025 | 666.20M | 73.94% |
| Dec 31, 2024 | 383.00M | -51.50% |
| Dec 29, 2023 | 789.70M | -19.57% |
| Dec 30, 2022 | 981.90M | -29.79% |
| Dec 31, 2021 | 1.40B | -17.57% |
| Dec 31, 2020 | 1.70B | 12.32% |
| Dec 31, 2019 | 1.51B | 0.48% |
| Dec 31, 2018 | 1.50B | 45.18% |
| Dec 29, 2017 | 1.04B | 110.87% |
| Dec 30, 2016 | 491.10M | 12.43% |
| Dec 31, 2015 | 436.80M | -41.71% |
View and export this data all the way back to 2015.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 902.96B |
| Johnson & Johnson | 487.28B |
| AbbVie | 400.12B |
| UnitedHealth Group | 299.52B |
| AstraZeneca | 280.82B |
| Novartis AG | 255.73B |
| Merck & Co. | 248.38B |
| Abbott Laboratories | 217.74B |